SpringWorks Therapeutics Bolsa (NASDAQ: SWTX)

Últimas noticias sobre SpringWorks Therapeutics (NASDAQ:SWTX) Bolsa

SpringWorks Therapeutics

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics Inc

Scotiabank analyst Patrick Colville maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Sector Perform and lowers the price target from $45 to $30.

News

Price Target

Analyst Ratings

TENB

Scotiabank Maintains Sector Perform on Tenable Holdings, Lowers Price Target to $30

Susquehanna analyst Bascome Majors maintains United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) with a Neutral and lowers the price target from $120 to $110.

Susquehanna Maintains Neutral on United Parcel Service, Lowers Price Target to $110

Scotiabank analyst Nick Altmann maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Sector Perform and raises the price target from $14 to $18.

FRSH

Scotiabank Maintains Sector Perform on Freshworks, Raises Price Target to $18

Susquehanna analyst Mehdi Hosseini maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Positive and lowers the price target from $155 to $133.

Susquehanna Maintains Positive on Teradyne, Lowers Price Target to $133

Scotiabank analyst Greg Harrison maintains BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Sector Outperform and raises the price target from $52 to $55.

BBIO

Scotiabank Maintains Sector Outperform on BridgeBio Pharma, Raises Price Target to $55

AVERSA Fentanyl has the potential to become the world's first opioid pain patch with abuse deterrent properties and is estimated to potentially reach peak annual sales of $80M - $200M. In addition, AVERSA Buprenorphine, our next candidate for AVERSA is projected to reach peak annual sales of $70M - $130M. Nutriband recently performed an extensive evaluation of the commercial cost of goods of incorporating the Aversa technology into existing FDA-approved transdermal patches and have confirmed the viability of achieving high margins that are typically found in NDA pharmaceutical products.

Guidance

NTRB

Earlier Reported: Nutriband CEO Said AVERSA Fentanyl Has The Potential To Become The World's First Opioid Pain Patch With Abuse Deterrent Properties And Is Estimated To Potentially Reach Peak Annual Sales Of $80M-$200M; AVERSA Buprenorphine, Our Next Candidate For Aversa Is Projected To Reach Peak Annual Sales Of $70M-$130M

Susquehanna analyst Shyam Patil maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Neutral and lowers the price target from $13 to $8.

SNAP

Susquehanna Maintains Neutral on Snap, Lowers Price Target to $8

Scotiabank analyst Maher Yaghi maintains American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) with a Sector Outperform and raises the price target from $234 to $248.

Scotiabank Maintains Sector Outperform on American Tower, Raises Price Target to $248

Susquehanna analyst Christopher Stathoulopoulos maintains Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Positive and lowers the price target from $295 to $275.

Susquehanna Maintains Positive on Royal Caribbean Gr, Lowers Price Target to $275

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) has outperformed the market over the past 15 years by 3.88% on an annualized basis producing an average annual return of 15.0%. Currently, Eaton Corp has a market capitalization of $114.58 billion. 
Buying $1000 In ETN: If an investor had bought $1000 of ETN stock 15 years ago, it would be worth $7,729.67 today based on a price of $289.94 for ETN at the time of writing.
<h3>Eaton Corp's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746030611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Eaton Corp 15 Years Ago Would Be Worth Today

Susquehanna analyst Charles Minervino maintains Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) with a Neutral and raises the price target from $22 to $25.

Susquehanna Maintains Neutral on Noble Corp, Raises Price Target to $25

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) board member Joe Gebbia made waves with a <a href="https://www.benzinga.com/news/insider-trades/25/04/45059696/airbnb-billionaire-joe-gebbia-buys-over-1-million-worth-of-tsla-stock-ahead-of-elon-musks-robotaxi-launch-in-june">$1 million insider stock purchase</a>—the company's first insider buy in years—just ahead of a planned stock sale by Chairwoman Robyn Denholm.
What Happened: Denholm has filed a new Form 144 that could carry out her pattern of <a href="https://www.benzinga.com/markets/equities/25/03/44099647/tesla-chair-robyn-denholm-sells-over-30-million-in-shares-as-stock-drops-nearly-3-amid-trump-tariff-concerns">exercising Tesla options</a> and selling off common shares, making millions of dollars in the process.
The <a href="https://www.sec.gov/Archives/edgar/data/1318605/000200731725000267/xsl144X01/primary_doc.xml">form </a>shows Denholm is planning to sell 112,390 Tesla shares for proceeds of around $32 million. The filing is part of a Rule 10b5-1, which means Denholm may have predetermined the transaction timing and share amounts and are not based on any insider information.
According to the filing, the latest transaction comes after Denholm exercised Tesla options acquired on June 18, 2018.
Denholm also sold the same number of shares (112,390) in February and March, with sales totaling $43.2 million and $33.7 million, respectively.
Benzinga contacted Tesla for clarification on the latest transaction and Denholm's remaining stake in the company but did not hear back.
The filing indicates that Denholm owns 85,000 Tesla shares and 300,440 options after the latest transaction.
As <a href="https://x.com/TeslaLarry/status/1917340125454799011">highlighted</a> by Tesla influencer "Tesla Larry" on social media, Denholm has exercised options previously, keeping a portion of the shares and selling others. Tesla Larry said the reports of Denholm selling shares are misleading as she is not liquidating her entire Tesla position and often increases her Tesla stake with the exercising of options.
Are you buying when the CEOs of the Magnificent 7 are selling? Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a>
Why It's Important: Denholm has been one of the most active sellers when it comes to Tesla insiders, with sales earlier this year in February and March. The Tesla Chairwoman also sold shares in March, May, July, November and December of 2024 according to <a href="https://www.benzinga.com/quote/TSLA/insider-trades">Benzinga's Insider Trades page.</a>
Denholm has received over $600 million in stock compensation since she joined the Tesla Board of Directors in 2014 and shas sold over $500 million in Tesla stock since that time, according to <a href="https://electrek.co/2025/04/29/tesla-tsla-chair-sells-most-of-her-stocks-her-time-is-done/">Electrek</a>.
Denholm became the Tesla Chairwoman in 2018 replacing Tesla CEO Elon Musk, who was required to step down from the role as part of an SEC settlement.
Some Tesla investors have been less than pleased with Denholm's hands-off role as Chairwoman and her constant selling of shares.
The latest filing by Denholm may completely overshadow the insider purchase made by Gebbia. While Gebbia's transaction was small in size at $1.03 million, it marked the first insider purchase in years and may signal increased confidence in Tesla ahead of robotaxis, FSD, new vehicle models and other coming catalysts.
Price Action: Tesla stock was down 5.1% to $277.14 on Wednesday, compared to a 52-week trading range of $167.41 to $488.54. Year-to-date in 2025, Tesla stock is down 26.8%, while shares have increased over 50% in the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44937440/tesla-q1-earnings-highlights-revenue-miss-eps-miss-tariff-landscape-and-changing-political-sentiment-cloud-guidance">Tesla Q1 Misses Estimates As Tariff Pressures Weigh On Outlook, Lower-Cost EVs Still On Track</a></li>
</ul>
Image: Midjourney

Management

Insider Trades

TSLA

Tesla Chairwoman Files To Sell More Stock Continuing Pattern Of Insider Sales At EV Giant

Susquehanna analyst James Friedman maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Positive and raises the price target from $100 to $125.

FOUR

Susquehanna Maintains Positive on Shift4 Payments, Raises Price Target to $125

Susquehanna analyst Joseph Stauff maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Neutral and raises the price target from $23 to $28.

Susquehanna Maintains Neutral on Caesars Entertainment, Raises Price Target to $28

Fresh Del Monte Produce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) shares are <a href="https://www.benzinga.com/movers">trading lower on Wednesday</a> after the first-quarter full year 2025 earnings.
The company reported a <a href="https://www.benzinga.com/pressreleases/25/04/b45093636/fresh-del-monte-produce-inc-reports-first-quarter-earnings-for-fiscal-2025">first-quarter revenue decline</a> of 0.9% year-on-year to $1.10 billion, missing the analyst consensus estimate of $1.11 billion.
The decrease in net sales was primarily driven by lower net sales in the company&#8217;s banana segment primarily as a result of lower sales volume and the negative impact of fluctuations in exchange rates.
Adjusted EPS of $0.63 <a href="https://www.benzinga.com/earnings">missed the consensus</a> estimate of $0.68.
Also Read: <a href="https://www.benzinga.com/news/25/04/45078934/dominos-pizza-will-grow-with-stuffed-crust-doordash-partnership-say-analysts">Domino&#8217;s Pizza Will Grow With Stuffed Crust &amp; DoorDash Partnership, Say Analysts</a>
Gross profit jumped 12% Y/Y to $92.2 million, and the profit margin expanded 100 basis points to 8.4%.
The operating margin was 4%, and operating income for the quarter remained flat at 44.9 million.
Adjusted EBITDA jumped 40.9% to $61.3 million with an adjusted EBITDA margin of 5.7%.
The operating cash flow for the quarter totaled $46.1 million.
On April 29, 2025, the company&#8217;s board of directors declared a quarterly cash dividend of $0.30 per share, payable on June 6, 2025, to shareholders of record on May 14, 2025.
The company held $34.4 million in cash and equivalents as of March 28, 2025. Long-term debt as of the end of the quarter decreased to $233 million from $244 million as of the end of 2024.
FDP Price Action:  Fresh Del Monte Produce shares traded lower by 3.19% at $33.66 at publication on Wednesday.
Read Next: • <a href="https://www.benzinga.com/news/25/04/45074719/levi-strauss-shareholders-stand-by-dei-policy-amid-political-pushback">Levi Strauss Shareholders Stand By DEI Policy Amid Political Pushback</a>
Photo: Postmodern Studio via Shutterstock

General

Fresh Del Monte Stock Falls As Q1 Sales, Earnings Miss Expectations

Wells Fargo analyst Aaron Rakers maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Equal-Weight and lowers the price target from $120 to $105.

Wells Fargo Maintains Equal-Weight on Seagate Tech Hldgs, Lowers Price Target to $105

Susquehanna analyst Shyam Patil maintains Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) with a Neutral and lowers the price target from $50 to $38.

CRTO

Susquehanna Maintains Neutral on Criteo, Lowers Price Target to $38

Wells Fargo analyst Aaron Rakers maintains CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) with a Overweight and raises the price target from $180 to $190.

CVLT

Wells Fargo Maintains Overweight on CommVault Systems, Raises Price Target to $190

Wells Fargo analyst Andrew Nowinski maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Overweight and lowers the price target from $50 to $40.

Wells Fargo Maintains Overweight on Tenable Holdings, Lowers Price Target to $40

Wells Fargo analyst Ken Gawrelski maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Equal-Weight and lowers the price target from $9 to $8.

Wells Fargo Maintains Equal-Weight on Snap, Lowers Price Target to $8

Health Care

Press Releases

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, RDUS, ALBT, BRDG on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

Comments

SpringWorks Therapeutics

Noticias

Últimas noticias sobre SpringWorks Therapeutics (NASDAQ:SWTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL